Liver failure

Keywords

1. miR-155 and acute liver failure
2. TNF-mediated hepatocyte apoptosis
3. MicroRNA role in liver disease
4. Inflammatory cytokines and liver injury
5. Acute liver failure (ALF) treatment research

Abstract

Acute liver failure (ALF) is a life-threatening condition requiring immediate medical attention. Recent advances in molecular biology have uncovered critical regulatory mechanisms involving microRNAs (miRNAs) that contribute to the pathogenesis of ALF through the regulation of apoptosis and cytokine synthesis. This article presents a comprehensive analysis of a noteworthy study that demonstrates the significance of miR-155 in mediating tumor necrosis factor (TNF)-related hepatocyte apoptosis in ALF mice models. Implications of these findings on both basic and clinical research fronts are discussed, along with potential therapeutic avenues.

Introduction

Acute liver failure (ALF), characterized by rapid loss of hepatocellular function, can result in significant morbidity and mortality. A complex interplay among various cytokines within the hepatic microenvironment orchestrates the cellular mechanisms leading to hepatocyte apoptosis and necrosis. Researchers have increasingly focused on investigating the role of microRNAs (miRNAs)—small non-coding RNAs that modulate gene expression post-transcriptionally—in liver diseases, including ALF, to uncover novel therapeutic targets.

A recent study published in The Turkish Journal of Gastroenterology by Zhang Guoqiang and colleagues (DOI: 10.5152/tjg.2019.18159) lays the foundation for understanding how up-regulation of miR-155 contributes to hepatocyte apoptosis in ALF via TNF signaling pathways. This article will explore the methodology and findings of the study, its clinical implications, and prompt a discussion on future research directions.

Methodology

Using a mouse model induced by D-Galactosamine/Lipopolysaccharide (D-GalN/LPS) to simulate ALF, the researchers performed miRNA microarray analysis to assess hepatic miRNA expression profiles. Subsequent verification was done by real-time quantitative polymerase chain reaction (RT-PCR). In-depth experiments included evaluating miR-155 expression in the liver, in spleen, and in vitro with activated Raw264.7 cells and Hepa1-6 cells under inflammatory conditions.

Results

The study pointed to a distinct change in the expression of several miRNAs related to apoptosis and necrosis of hepatocytes in the ALF mouse model, with miR-155 being notably up-regulated. Correlations were established between miR-155 levels and inflammatory cytokines, such as TNF and IL-6. In vivo, miR-155 was found to be elevated throughout the examination period in the liver, and at specific time points in the spleen. The in vitro analysis provided additional support for the regulatory roles of miR-155 in TNF expression upon LPS or D-GalN+TNF induction, suggesting a mechanism whereby miR-155 modulates TNF-mediated apoptosis.

Discussion

The findings of Zhang Guoqiang et al. provide exciting new insights into the complex modulation of the immune response during ALF. miR-155 appears to be a critical contributor in amplifying the inflammatory signals leading to TNF-mediated hepatocyte apoptosis. The study’s outcomes resonate with prior investigations on miRNA mechanics, reinforcing the notion that miRNAs are potential therapeutic targets for inflammatory diseases (Gambardella et al., 2017; Lee et al., 2016).

Clinical Implications

By validating the role of miR-155, this research offers a glimpse into the potential therapeutic applications for mitigating ALF. Antagonizing miR-155 or disrupting its signalling pathways could be a strategic approach to curtailing excessive inflammation and hepatocyte apoptosis, ultimately improving patient outcomes. Recent therapeutic strategies involving the modulation of miRNA activity (Xuan et al., 2015) suggest the feasibility of this approach, despite the need for comprehensive clinical trials to ensure efficacy and safety.

Future Research and Conclusion

Further research needs to elucidate the complete spectrum of miRNA interactions in ALF and their translation to human models. Understanding the multifaceted roles of other inflammatory cytokines and their regulation by miRNAs (Huang et al., 2010) could provide a holistic view of the disease mechanism.

Establishing translatable models and innovative delivery systems (Zeng et al., 2016; Mosoian et al., 2016) for miRNA-based therapeutics will be essential for the next steps in clinical applications. As inflammation remains a central component in various liver pathologies, these discoveries not only benefit acute conditions like ALF but also chronic liver diseases, potentially changing the landscape of hepatology treatment frameworks.

References

1. Wang X, Ning Q. “Immune mediated liver failure.” EXCLI J. 2014;13:1131–44. PMC4464508. DOI: 10.5152/tjg.2019.18159.
2. An F, Gong B, Wang H, et al. “miR-15b and miR-16 regulate TNF mediated hepatocyte apoptosis via BCL2 in acute liver failure.” Apoptosis. 2012;17:702–16. DOI: 10.1007/s10495-012-0704-7.
3. Xu Y, Wang H, Bao S, et al. “Amelioration of liver injury by continuously targeted intervention against TNFRp55 in rats with acute-on-chronic liver failure.” PLoS One. 2013;8:e68757. DOI: 10.1371/journal.pone.0068757.
4. Gambardella G, Carissimo A, Chen A, et al. “The impact of microRNAs on transcriptional heterogeneity and gene co-expression across single embryonic stem cells.” Nat Commun. 2017;8:14126. DOI: 10.1038/ncomms14126.
5. Xuan Y, Yang H, Zhao L, et al. “MicroRNAs in colorectal cancer: small molecules with big functions.” Cancer Lett. 2015;360:89–105. DOI: 10.1016/j.canlet.2014.11.051.
6. Lee HM, Kim TS, Jo EK. “MiR-146 and miR-125 in the regulation of innate immunity and inflammation.” BMB Rep. 2016;49:311–8. DOI: 10.5483/BMBRep.2016.49.6.056.
7. Chen Y, Zeng Z, Shen X, et al. “MicroRNA-146a-5p Negatively Regulates Pro-Inflammatory Cytokine Secretion and Cell Activation in Lipopolysaccharide Stimulated Human Hepatic Stellate Cells through Inhibition of Toll-Like Receptor 4 Signaling Pathways.” Int J Mol Sci. 2016;17. DOI: 10.3390/ijms17071076.
8. Huang RS, Hu GQ, Lin B, et al. “MicroRNA-155 silencing enhances inflammatory response and lipid uptake in oxidized low-density lipoprotein-stimulated human THP-1 macrophages.” J Investig Med. 2010;58:961–7. DOI: 10.2310/JIM.0b013e3181ff46d7.
9. Tili E, Michaille JJ, Cimino A, et al. “Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock.” J Immunol. 2007;179:5082–9. DOI: 10.4049/jimmunol.179.8.5082.
10. Shirozu K, Tokuda K, Marutani E, et al. “Cystathionine γ-lyase deficiency protects mice from galactosamine/lipopolysaccharide-induced acute liver failure.” Antioxid Redox Signal. 2014;20:204–16. DOI: 10.1089/ars.2013.5354.